Beyond sharing data, DQS aligns multiple data sources, including sponsors’ clinical trial management system data, public registries, and clinical trial databases, to provide a single, holistic, and ...

Jonathan Andrus, co-CEO of CRIO, explains how protocol-driven eSource templates and standardized data capture are improving ...

The emergence of AI and biosensors offers a chance to address inefficiencies in drug development.

In paediatrics, “more trials have been done over the last ten years, but we have struggled with transparency and clarity, and sometimes with the quality because they are not always asking the ...

When discussing the future of clinical trials, people often focus on the promise of exciting new technologies, including artificial intelligence (AI) and predictive modeling. However, even the most ...

GREENVILLE, S.C.--(BUSINESS WIRE)--Avallano is launching ProtocolCopilot™, an innovative AI-driven clinical research protocol assistant designed to transform the way biopharmaceutical companies and ...

This study used surveys and live interviews. Forty-one major industry and National Cancer Institute Network groups (sponsors) overseeing anticancer treatment trials open in the United States from ...

The lack of a mechanism to measure the workload involved in a clinical trials protocol was identified and confirmed by a literature review. To collect information on how Ontario sites were assessing ...

Diversity in clinical trials matters for drug safety and efficacy—and for future medical advancements. Clinical trial ...

Tissue biopsies can be important parts of testing new drugs, and the FDA has now issued a draft guidance with recommendations for when they should be included in clinical trial protocols. The draft ...